Medigene AG (XTER:MDG1) 3-Year Revenue Growth Rate : -9.00% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Medigene AG 3-Year Revenue Growth Rate?

Medigene AG's Revenue per Share for the six months ended in Dec. 2023 was €0.12.

During the past 12 months, Medigene AG's average Revenue per Share Growth Rate was -80.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was -9.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 6.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was -5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Medigene AG was 46.70% per year. The lowest was -56.50% per year. And the median was -7.25% per year.

Competitive Comparison of Medigene AG's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Medigene AG's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medigene AG's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigene AG's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Medigene AG's 3-Year Revenue Growth Rate falls into.

Medigene AG 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Medigene AG (XTER:MDG1) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Medigene AG 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Medigene AG's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigene AG (XTER:MDG1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (XTER:MDG1) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

MDGEF:USA MDG1:Austria

Address

Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.medigene.com

Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

Medigene AG (XTER:MDG1) Headlines

No Headlines